Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?
- PMID:19226264
- PMCID: PMC3654652
- DOI: 10.1111/j.1365-2265.2009.03556.x
Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?
Abstract
Monitoring of a patient with acromegaly requires periodic evaluation of levels of GH and IGF-1, the biochemical markers of this disease. Although the results of these two tests are usually concordant, they can be discrepant and how to proceed when they are can be a challenging clinical problem. In some cases, IGF-1 levels are normal yet GH suppression after oral glucose is abnormal; this pattern may be due to persistent GH dysregulation despite remission. In other cases, IGF-1 levels are elevated yet GH suppression appears to be normal; this pattern may be observed if the cutoff for GH suppression is inappropriately high for the GH assay being used. Various conditions known to alter GH and IGF-1 including malnutrition, thyroid disease and oestrogen use as well as the potential for methodological or normative data issues with the GH and IGF-1 assays should be considered in the interpretation of discrepant results. When a known cause of the discrepancy other than acromegaly is not identified, a clinical decision about the patient's therapy needs to be made. We adjust treatment in most patients whose results are discrepant based on the IGF-1 level, continuing current treatment if it is persistently normal or modifying this if it is elevated. The clinical picture of the patient, however, also needs to be incorporated into this decision. All patients should have continued periodic surveillance of both GH and IGF-1 levels.
References
- Freda PU, Post KD, Powell JS, et al. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. Journal of Clinical Endocrinology and Metabolism. 1998;83:3808–3816. - PubMed
- Dimaraki EV, Jaffe CA, DeMott-Friberg R, et al. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. Journal of Clinical Endocrinology and Metabolism. 2002;87:3537–3542. - PubMed
- Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Hormone and IGF Research. 2003;13:171–184. - PubMed
- Costa AC, Rossi A, Martinelli Jr CE, et al. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? . Journal of Clinical Endocrinology and Metabolism. 2002;87:3142–3147. - PubMed
- Chapman IM, Hartman ML, Straume M, et al. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. Journal of Clinical Endocrinology and Metabolism. 1994;78:1312–1319. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous